Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Related HLA-haploidentical blood or marrow transplantation (BMT) with high-dose posttransplantation cyclophosphamide (PTCy) is being increasingly used because of its acceptable safety profile. To better define outcomes of nonmyeloablative (NMA) HLA-haploidentical BMT with PTCy, 372 consecutive adult...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: McCurdy, Shannon R., Kanakry, Jennifer A., Showel, Margaret M., Tsai, Hua-Ling, Bolaños-Meade, Javier, Rosner, Gary L., Kanakry, Christopher G., Perica, Karlo, Symons, Heather J., Brodsky, Robert A., Gladstone, Douglas E., Huff, Carol Ann, Pratz, Keith W., Prince, Gabrielle T., Dezern, Amy E., Gojo, Ivana, Matsui, William H., Borrello, Ivan, McDevitt, Michael A., Swinnen, Lode J., Smith, B. Douglas, Levis, Mark J., Ambinder, Richard F., Luznik, Leo, Jones, Richard J., Fuchs, Ephraim J., Kasamon, Yvette L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424420/
https://ncbi.nlm.nih.gov/pubmed/25814532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-623991
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados